Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 3,524 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Saline (Placebo Control) Clear all
Not listed Phase 4 Interventional Accepts healthy volunteers

Addition of Clonidine to Ropivacaine in Adductor Canal Block

NCT03057015
View directory record Official record
Conditions
Postoperative Pain
Interventions
Clonidine, Placebo, Ropivacaine, Dexamethasone, Epinephrine
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Oct 15, 2026, 4:06 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Effects of GLYX-13 on Learning and Memory in Healthy Individuals and Those With Psychiatric Illness

NCT01844726
View directory record Official record
Conditions
Psychiatric Illness, Healthy
Interventions
GLYX-13, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 40 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 15, 2026, 4:06 PM EDT
Withdrawn Phase 1 Interventional

Superselective Citicoline and Verapamil for Ischemic Neuroprotection and Greater Effective Response

NCT02823106
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Verapamil and Citicoline, Placebo
Drug · Other
Lead sponsor
Justin Fraser
Other
Eligibility
18 Years to 101 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 15, 2026, 4:06 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Lidocaine For Treatment of Post-operative Pain From Donor Sites Following Burn Injury.

NCT02229578
View directory record Official record
Conditions
Pain
Interventions
Lidocaine, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 15, 2026, 4:06 PM EDT
Terminated Phase 3 Interventional Results available

Botox for Non-surgical Lateral Release in Patellofemoral Pain

NCT00496964
View directory record Official record
Conditions
Patellofemoral Pain Syndrome
Interventions
Botulinum toxin A + exercise, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 40 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Oct 15, 2026, 4:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI

NCT02134314
View directory record Official record
Conditions
End Stage Renal Disease, Kidney Failure, Delayed Graft Function, Ischemic Reperfusion Injury
Interventions
C1 Esterase Inhibitor, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Oct 15, 2026, 4:06 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Nitric Oxide Bioavailability and Early Life Stress (NO-Stress)

NCT02115724
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Antioxidant cocktail, Biopsy, Placebo, NMD; 0.4mg sub-lingual nitroglycerin spray
Dietary Supplement · Other · Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 40 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 15, 2026, 4:06 PM EDT
Completed Phase 3 Interventional Results available

Pediatric Tonsillectomy Pain Reduction Study

NCT00678379
View directory record Official record
Conditions
Postoperative Pain
Interventions
lidocaine (1%) + bupivacaine (0.5%), Normal saline, Lidocaine (1%) + Bupivacaine (0.5%) + Clonidine (25mcg)
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
3 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 15, 2026, 4:06 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Multimodal Uterotonics at the Time of Cesarean Section in Laboring Patients

NCT03904446
View directory record Official record
Conditions
Uterine Atony With Hemorrhage
Interventions
Methylergonovine, Normal Saline (placebo)
Drug
Lead sponsor
Cynthia Wong
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 15, 2026, 4:06 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Intranasal Lidocaine for Prevention of Postoperative Nausea and Vomiting.

NCT04810494
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
2% Lidocaine HCl topical solution, 0.9% Sodium chloride
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Oct 15, 2026, 4:06 PM EDT
Withdrawn Phase 2 Interventional

The Use of Ketorolac in Surgical Neonates

NCT01667120
View directory record Official record
Conditions
Postoperative Pain Control in Surgical Neonates
Interventions
Ketorolac, placebo
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Week to 3 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 15, 2026, 4:06 PM EDT
Not listed Phase 2 Interventional

Microbiota Transfer Therapy for Children and Adults With Both Pitt Hopkins Syndrome and Gastrointestinal Disorders

NCT06321796
View directory record Official record
Conditions
Pitt Hopkins Syndrome
Interventions
MTP-101P, Vancomycin, Magnesium Citrate, Antacid, Placebo MTP-101P, Placebo Vancomycin
Combination Product
Lead sponsor
Gut-Brain-Axis Therapeutics Inc.
Other
Eligibility
5 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 15, 2026, 4:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of an HIV Preventive Vaccine Given With or Without an Adjuvant in HIV Uninfected Adults

NCT00111605
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 gag DNA, HIV-1 gag DNA plus IL-12 DNA adjuvant, CTL MEP/RC529-SE/GM-CSF (CTL MEP vaccine), Sodium chloride injection (0.9%)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2008
U.S. locations
3
States / cities
Birmingham, Alabama • Baltimore, Maryland • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 15, 2026, 4:06 PM EDT
Completed Phase 4 Interventional Results available

Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial

NCT05822583
View directory record Official record
Conditions
COVID-19
Interventions
abatacept infusion, Placebo group
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
82
States / cities
Birmingham, Alabama • Tucson, Arizona • Davis, California + 58 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 15, 2026, 4:06 PM EDT
Terminated Phase 2 Interventional Results available

Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003)

NCT03960541
View directory record Official record
Conditions
HIV Infections, Dyslipidemias
Interventions
Efprezimod alfa (human CD24 extracellular domain and human IgG1 Fc fusion protein), Saline Solution
Drug
Lead sponsor
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
50 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 15, 2026, 4:06 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.

NCT03769194
View directory record Official record
Conditions
Lyme Borreliosis
Interventions
VLA15, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
572 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
6
States / cities
Milford, Connecticut • Stamford, Connecticut • Binghamton, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 15, 2026, 4:06 PM EDT
Recruiting Phase 4 Interventional

Indigotindisulfonate Sodium as an Aid in Determination of Ureteral Patency in Patient's With Renal Impairment

NCT06085183
View directory record Official record
Conditions
Ureter Injury
Interventions
Saline Injection 0.9%, Indigotindisulfonate sodium 0.8%
Other · Drug
Lead sponsor
Prove pharm
Industry
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 15, 2026, 4:06 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

GLP-1 and Hypoglycemia

NCT01858896
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Glucagon-Like Peptide- 1 (GLP-1) infusion, Placebo Comparator: Saline Infusion
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 15, 2026, 4:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate the Pharmacokinetics (PK), Safety and Tolerability of Retosiban in Healthy Japanese Women

NCT02377414
View directory record Official record
Conditions
Obstetric Labour, Premature
Interventions
Retosiban solution for Infusion, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
20 Years to 45 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 15, 2026, 4:06 PM EDT
Active, not recruiting Phase 4 Interventional

Propofol-Enhanced Assessment of Ketamine for Chronic Pain and Depression

NCT06317636
View directory record Official record
Conditions
Chronic Pain, Depression
Interventions
Ketamine, Normal saline
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 15, 2026, 4:06 PM EDT
Completed Phase 4 Interventional Results available

Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia

NCT01614093
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 54 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 15, 2026, 4:06 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS

NCT05938036
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS)
Interventions
ALT-100 mAb, ALT-100 (Placebo)
Drug
Lead sponsor
Aqualung Therapeutics Corp.
Industry
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 15, 2026, 4:06 PM EDT
Withdrawn Not applicable Interventional

Prontosan Versus Saline in the Cleansing of Chronic Leg Ulcers in Diabetic Patients

NCT01554644
View directory record Official record
Conditions
Diabetic Complications
Interventions
Prontosan, Saline
Device
Lead sponsor
B. Braun Medical Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
San Diego, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Oct 15, 2026, 4:06 PM EDT
Completed Phase 2 Interventional Results available

Smell in Covid-19 and Efficacy of Nasal Theophylline

NCT04789499
View directory record Official record
Conditions
Covid19, Anosmia, Olfactory Disorder, Covid-19 Pandemic, SARS-CoV-2 Infection, Hyposmia, Ageusia, Hypogeusia
Interventions
Theophylline Powder, Placebo Comparator
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 15, 2026, 4:06 PM EDT